November 28, 2018— In a recent commentary published in the Journal of the American Medical Association (JAMA), authors Peter Bach of Memorial Sloan Kettering Cancer Center and Rachel Sachs of Washington University in St. Louis call for an alternative financial mechanism for the 340B program, claiming the 340B program has resulted in market distortions and shifts in physician … [Read more...]
Busy times for 340B in Washington
November 19, 2018—The midterm elections were not the only source of Washington-related news in recent weeks with implications for the health care system. When it comes to 340B, several key events occurred in the days leading up to Election Day that might have longer-lasting implications for the program than the makeup of the 116th Congress. White House thinks globally on … [Read more...]
Congressional Leader Urges Medicare to Reverse 340B Hospital Cuts
October 19, 2018—Responding to a call for help from hospital CEOs in his home state and across the country, U.S. Senate Minority Leader Chuck Schumer (D-N.Y.) has urged Trump administration health officials to reverse a nearly 30 percent cut in Medicare Part B drug reimbursement to hospitals in the 340B drug pricing program. Speaking at United Memorial Medical Center (UMMC) … [Read more...]
340B Health and Other Groups Sue HHS Challenging Delay of 340B Regulation
September 11, 2018—Today, 340B Health and three other national hospital associations have filed suit to force the U.S. Department of Health and Human Services (HHS) to enforce rules prohibiting manufacturers from overcharging 340B providers. The suit also would compel HHS to post 340B ceiling prices on a secure website. In 2010, Congress responded to a series of reports by … [Read more...]
Writing in The New York Times, Economist Ignores Research Showing 340B Is Working
September 7, 2018—Healthcare economist Austin Frakt recently wrote in The New York Times that the 340B drug discount program includes hospitals “that don’t need the extra help” and don’t use the program to benefit low-income patients. That’s a one-sided view that ignores research showing 340B is working as Congress intended. The research Frakt overlooks includes findings … [Read more...]
Faces of 340B: Lifesaving Care During Disasters
August 23, 2018—Hurricane Harvey made landfall in Texas just over a year ago, dumping more than 40 inches of rain in the Houston metropolitan area. More than 30,000 people were displaced in the resulting floods. It also created a public health crisis that demanded a rapid response. The Centers for Disease Control and Prevention (CDC) recommends that responders to disasters … [Read more...]
New Independent Study Confirms 340B is a Small Share of U.S. Drug Market
August 8, 2018—A new report by independent researchers refutes claims by the pharmaceutical industry that the 340B drug pricing program is so large it forces manufacturers to raise their prices. Writing in the Health Affairs Blog, a team of researchers from the Pew Charitable Trusts found the 340B program is only 1.4 percent of gross U.S. drug sales. This confirms earlier … [Read more...]